[Buckner JC. Factors influencing survival in high-grade gliomas. Semin Oncol 2003; 30(6 Suppl 19): 10-4.10.1053/j.seminoncol.2003.11.031]Search in Google Scholar
[Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10.10.1093/jnci/85.9.704]Search in Google Scholar
[Baur M, Preusser M, Piribauer M, Elandt K, Hassler M, Hudec M, et al. Frequent MGMT (06-methylguanine-DNA methyltransferase) hypermethylation in long-term survivors of glioblastoma: a single institution experience. Radiol Oncol 2010; 44: 113-20.10.2478/v10019-010-0023-y]Search in Google Scholar
[Chakrabarti I, Cockburn M, Cozen W, Wang YP, Preston-Martin S. A population-based description of glioblastoma multiforme in Los Angeles County, 1974-1999. Cancer 2005; 104: 2798-806.10.1002/cncr.21539]Search in Google Scholar
[Kachanov DY, Dobrenkov KV, Shamanskaya TV, Abdullaev RT, Inushkina EV, Savkova RF, et al. Solid tumors in young children in Moscow Region of Russian Federation. Radiol Oncol 2008; 42: 39-44.10.2478/v10019-007-0037-2]Search in Google Scholar
[Stupp R, Tonn JC, Brada M, Pentheroudakis G; ESMO Guidelines Working Group. High-grade malignant glioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21(Suppl 5): 190-3.10.1093/annonc/mdq187]Search in Google Scholar
[Stewart LA. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 2002; 359: 1011-8.10.1016/S0140-6736(02)08091-1]Search in Google Scholar
[Stupp R, Gander M, Leyvraz S, Newlands E. Current and future developments in the use of the for the treatment of brain tumours. Lancet Oncol 2001; 2: 552-60.10.1016/S1470-2045(01)00489-2]Search in Google Scholar
[Stupp R, Hegi ME. Recent developments in the management of malignant glioma. In: Perry M, editor. ASCO 2003 educational book. Alexandria, VA: American Society of Clinical Oncology; 2003. p. 779-88.]Search in Google Scholar
[DeAngelis LM. Brain tumors. N Engl J Med 2001; 344: 114-23.10.1056/NEJM20010111344020711150363]Search in Google Scholar
[Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.10.1056/NEJMoa04333015758009]Search in Google Scholar
[Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-10.10.1093/jnci/85.9.7048478956]Search in Google Scholar
[Mahaley MS Jr, Mettlin C, Natarajan N, Laws ER Jr, Peace BB. National survey of patterns of care for brain-tumor patients. J Neurosurg 1989; 71: 826-36.10.3171/jns.1989.71.6.08262585073]Search in Google Scholar
[Stupp R, Hegi ME, van den Bent MJ, Mason WP, Weller M, Mirimanoff RO, et al. Changing paradigms - An update on the multidisciplinary management of malignant glioma. Oncologist 2006; 11: 165-80.10.1634/theoncologist.11-2-16516476837]Search in Google Scholar
[Khasraw M, Bell D, Wheeler H. Long-term use of temozolomide: could you use temozolomide safely for life in gliomas? J Clin Neurosci 2009, 16: 854-5.10.1016/j.jocn.2008.09.00519303779]Search in Google Scholar
[Khasraw M, Lassman AB. Advances in the treatment of malignant gliomas. Curr Oncol Rep 2010; 12: 26-33.10.1007/s11912-009-0077-420425605]Search in Google Scholar
[Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S. Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 2009; 95: 191-7.10.1177/030089160909500210]Search in Google Scholar
[Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.10.1056/NEJMoa04333115758010]Search in Google Scholar
[Velnar T, Smrdel U, Popovic M, Bunc G. Genetic markers in oligodendroglial tumours. Radiol Oncol 2010; 44: 13-8.10.2478/v10019-010-0007-y342367522933885]Search in Google Scholar
[Komotar RJ, Otten ML, Moise G, Connolly, Jr. ES. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma - a critical review. Clinical Medicine: Oncology 2008: 2: 421-2.10.4137/CMO.S390]Search in Google Scholar
[Gerstein J, Franz K, Steinbach JP, Seifert V, Fraunholz I, Weiss C, et al. Postoperative radiotherapy and concomitant temozolomide for elderly patients with glioblastoma. Radiother Oncol 2010; 97: 382-6.10.1016/j.radonc.2010.06.01420850883]Search in Google Scholar
[Walker MD, Strike TA, Sheline GE. An analysis of doseeffect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys 1979; 5: 1725-31.10.1016/0360-3016(79)90553-4]Search in Google Scholar
[Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4 astrocytoma. The Medical Research Council Brain Tumour Working Party. Br J Cancer 1991; 64: 769-74.]Search in Google Scholar
[Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORT C 26981/22981-NCIC CE3 phase - III randomized trial. J Clin Oncol 2006; 24: 2563-9.10.1200/JCO.2005.04.596316735709]Search in Google Scholar